Vaccine Effectiveness against GP-Attended Symptomatic COVID-19 and Hybrid Immunity among Adults in Hungary during the 2022-2023 Respiratory Season Dominated by Different SARS-CoV-2 Omicron Subvariants.

Judit Krisztina Horváth, Gergő Túri, Katalin Krisztalovics, Katalin Kristóf, Beatrix Oroszi

Abstract read

In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Primary Care-Based Estimates of Influenza Vaccine Effectiveness in Hungary, 2024/25.Vaccines · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Judit Krisztina HorváthNational Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, 1085 Budapest, Hungary.ORCID 0009-0001-7402-3227

Gergő TúriNational Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, 1085 Budapest, Hungary.

Katalin KrisztalovicsNational Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, 1085 Budapest, Hungary.

Katalin KristófInstitute of Laboratory Medicine, Clinical Microbiology Laboratory, Semmelweis University, 1085 Budapest, Hungary.

Beatrix OrosziNational Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, 1085 Budapest, Hungary.

Funding

National Research Development and Innovation Office RRF-2.3.1-21-2022-00006

6 · The paper itself

Abstract

Hungary provides the opportunity to evaluate the effectiveness of COVID-19 vaccination in a setting where naturally acquired immunity and hybrid immunity are likely to play a greater role due to suboptimal vaccination coverage.

methodsA test-negative study was conducted during the 2022-2023 respiratory season at the primary care level to determine the effectiveness of at least one COVID-19 booster dose in preventing medically attended symptomatic RT-PCR-confirmed SARS-CoV-2 infection in adults. Unvaccinated patients were used as a reference group.

resultsA total of 247 cases and 1073 controls were included in the analysis. CVE was 56.8% (95% CI: 11.9-78.8%) in the population aged 60 years and older and 2.3% (95% CI: -50.0-36.3%) in the younger adults against COVID-19 caused by Omicron subvariants, mainly BA.5, BQ.1, and XBB.1. Self-reported COVID-19 in the 60-365 days prior to the current illness did not confer protection against reinfection without vaccination, but together with booster vaccination, it reduced the risk of COVID-19 by 63.0% (95% CI: -28.0-89.3%) and 87.6% (95% CI: 26.4-97.9%) among the 18-59 and 60+ age groups, respectively.

conclusionsCVE against COVID-19 was moderately high in the 60+ age groups. Because of the benefit of hybrid immunity, persons with previous SARS-CoV-2 infection should still be considered for vaccination campaigns.

Indexed as

booster vaccinationCOVID-19hybrid immunityOmicron subvariantsprimary carereinfectionSARS-CoV-2test-negative designvaccine effectiveness

Identifiers

PMID38793747

DOI10.3390/vaccines12050496

PMCPMC11125656

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.